Brought to you by 
TriPath to develop cancer tests for BD and Millennium
03 Apr 2002
Executive Summary
TriPath Imaging's (cervical cancer diagnostics) oncology division, TriPath Oncology (created specifically to manage activities related to this alliance) will develop and market molecular diagnostics and pharmacogenomic cancer tests for Becton Dickinson under BD's ongoing 1999 deal with Millennium Pharmaceuticals.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TriPath to develop cancer tests for BD and Millennium
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice